Compare Heron Therapeutics Inc (HRTX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Xylem, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 350.1× Heron Therapeutics Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Xylem, Inc. for 50 Days on average.
| HRTX | XYL | |
|---|---|---|
Market Cap | $68.01M | $23.81B |
Volume | 1,891,941 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $1.49 | $152.95 |
52-Week Low | $0.27 | $100.92 |
Typical Hold Time | 35 Days | 50 Days |
Enterprise Value | $174.75M | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
XYL trades at $102.71, up 0.86% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $9.04B in 2025 with a net income margin of 10.59%, and has beaten EPS estimates in recent quarters. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, and the appointment of a new CFO.
Outlook is supported by strong water-solutions demand and margin expansion, but risks include China weakness and higher debt. Analysts are mixed with a consensus price target of $149.13, implying significant upside from current levels, though near-term technical pressure may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
